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A B S T R A C T
G-CSF was among the ﬁrst cytokines to be identiﬁed and rapidly transitioned into clinical medicine.
Initially used to promote the production of neutrophils in patients with chemotherapy-induced
neutropenia it helped to revolutionize the delivery of cancer therapy. Its ability to mobilize
hematopoietic stem cells from the bone marrow into the blood was subsequently exploited, changing
the face of hematopoietic stem cell transplantation. Today the knowledge gained in unraveling the
mechanisms of stem cell mobilization by G-CSF is being explored as a means to increase
chemosensitivity in hematological malignancies. This review provides a brief history of G-CSF and
then focuses on recent advances in our understanding of G-CSF-induced stem cell mobilization and the
potential clinical application of this knowledge in chemo-sensitization.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Granulocyte colony stimulating factor (G-CSF) was among the
ﬁrst cytokines to be identiﬁed and to enter clinical trials. The
identiﬁcation of G-CSF followed the development of an assay
measuring the effects of G-CSF and related cytokines by two
independent groups in the 1960s: Ray Bradley and Don Metcalf at
the University of Melbourne, Australia, and Yasuo Ichikawa and
Leo Sachs at the Weizmann Institute, Israel [1,2]. These assays
measured the ability of test agents to stimulate colony formation in
hematopoietic cells in semi-solid culture and gave many of these
cytokines their names, e.g. granulocyte colony stimulating factor,
granulocyte/macrophage colony stimulating factor etc. Although
colony forming assays permitted the quantitation of G-CSF, it was
more than a decade before Nicos Nicola in Donald Metcalf’s
laboratory ﬁnally isolated the murine cytokine from medium
conditioned with the lung tissue obtained from endotoxin treated
mice in 1983 [3]. Human G-CSF was puriﬁed soon after from the
conditioned medium of the bladder carcinoma cell line 5637 by
Karl Welte in 1985 [4]. The concurrent development of molecular
biology techniques meant that the G-CSF gene was soon cloned by
Shigekazu Nagata in Japan and independently by Lawrence Souza
from AMGEN in 1986, permitting the large scale production of this
cytokine and its subsequent clinical application [5,6].
2. Biology of G-CSF
G-CSF is central to the production of neutrophils in health and
diseased states and is responsible for the dramatic increase in
neutrophil numbers in response to infection or insults affecting
bone marrow function such as anti-cancer cytotoxic chemothera-
py. The ability of G-CSF to induce the production of mature
neutrophils is evident from the production of neutrophilic
granulocyte colonies from bone marrow cells in semi-solid
cultures in response to this cytokine [7]. Furthermore mice lacking
G-CSF or its receptor, G-CSFR, demonstrate chronic severe
neutropenia, although a small number of neutrophils are still
detected [8,9].
G-CSF mediates its effects by binding to a single homodimer
receptor, G-CSFR [10]. Plasma concentrations of G-CSF are
normally low to undetectable, but rise rapidly in response to
infection and subsequently decline with recovery [11,12]. Many
tissues can produce G-CSF when appropriately stimulated, with
inﬂammatory mediators such as lipopolysaccharide (LPS), tumor
necrosis factor (TNF)-a, interferon (IFN)-b, vascular endothelial
growth factor (VEGF), interleukin (IL)-17 and IL-1 inducing
expression in endothelial cells, macrophages, epithelial cells and
ﬁbroblasts [13–15]. The release of G-CSF into the bloodstream by
tissues stimulates neutrophil production within, and mobilization
from, the bone marrow. Furthermore, the locally produced G-CSF
within tissues also inﬂuences the function of neutrophils at the site
of infection. G-CSF can inhibit neutrophil apoptosis [16], increasing
survival within infected tissues [17]. Although G-CSF does not
directly induce the chemotaxis of neutrophils it has chemokinetic
activity on these cells, promoting non-directional motility [18],
which increases responses to chemotactic factors such as thebacterial agent N-Formyl-Methionine-Leucine-Phenylalanine
(fMLP) [19]. Whether this contributes to the increased accumula-
tion of neutrophils in inﬂamed tissues is not certain but G-CSF does
not promote neutrophil migration through TNF-a activated
endothelium [18]. Similarly, while G-CSF does not directly
stimulate phagocytosis or superoxide generation, it primes
neutrophils, augmenting responses to agents such as fMLP [20].
This suggests that G-CSF may facilitate the activity of neutrophils
within an inﬂammatory environment but has little effect under
normal physiological situations, thereby restricting these activities
of neutrophils to sites of infection.
2.1. G-CSF in the treatment of neutropenia and bone marrow failure
syndromes
The ﬁrst clinical trials of G-CSF were for the reduction of
chemotherapy-induced neutropenia and infections in cancer
patients [21,22]. Subsequent randomized multicenter trials from
the USA and Europe demonstrated that G-CSF reduced the
incidence of febrile neutropenia and culture-conﬁrmed infections.
G-CSF also reduced the incidence, duration, and severity of grade IV
neutropenia, which translated into reduced intravenous antibiotic
use and shorter hospitalization periods [23,24]. The use of G-CSF
also increased the likelihood that patients would receive their
planned dose of chemotherapy [23]. Today G-CSF is routinely given
to patients receiving chemotherapy for a range of malignancies, in
particular in situations where the risk of severe neutropenia is
estimated to be over 20%, and also to allow for the delivery of
‘‘dose-dense’’ chemotherapy regimens, as outlined in the 2005
ASCO guidelines [25].
G-CSF is also used to treat isolated congenital, cyclic, and
idiopathic neutropenia and some cases of myelodysplastic
syndrome and acquired aplastic anemia. In patients with isolated
neutropenia, G-CSF reduces symptoms with fewer occurrences of
mouth ulcers, febrile events, and infections [26]. In aplastic anemia
the results are less clear cut with measurable beneﬁts only being
seen in the most severe cases and limited to reduced infectious
events, but no overall effect on survival [27]. While chronic
neutropenias are rare, these patients have an ongoing need for G-
CSF and in contrast to patients experiencing chemotherapy-
induced neutropenia, require a more reﬁned and personalized
dosing regimen. Side effects and adverse events also pose a greater
risk and inconvenience to patients with chronic neutropenia. Some
of the more acute effects, such as bone pain, can be successfully
managed by optimizing the dosing schedule [28]. The longer-term
and more concerning risks of myelodysplastic syndrome (MDS)
and acute myeloid leukemia (AML) are more difﬁcult to assess as
they form part of the natural history of some of these conditions.
While patients with congenital neutropenia requiring higher doses
of G-CSF are now known to have an increased incidence of MDS
and AML [29] it remains impossible to be certain that G-CSF has
contributed to the development of these conditions although at
this stage this is thought to be unlikely. The use of G-CSF in
inherited clonal conditions such as Fanconi anemia is not
recommended due to limited beneﬁt and a perceived increased
risk of AML.
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3.1. Origins
Bone marrow transplantation (also now termed hematopoietic
cell transplantation (HCT)) is the oldest form of anti-cancer
immunotherapy in clinical use, and involves the transplantation of
hematopoietic stem and progenitor cells from self (autologous) or
histocompatible allogeneic related or unrelated volunteer donors.
Autologous HCT is carried out using cryopreserved hematopoietic
cells to restore marrow function after the delivery of high dose
chemotherapy, predominantly for patients with lymphomas or
multiple myeloma [30,31]. Allogeneic HCT is also used to restore
hematopoiesis and immune function in patients with bone
marrow failure and immunodeﬁciency syndromes, but is now
most commonly used as cellular immune therapy to treat patients
with hematopoietic malignancies [32,33].
Traditionally, hematopoietic cells for both autologous and
allogeneic transplantation were obtained by collecting large
volumes of bone marrow, aspirated from the pelvic crests under
general anesthesia. However, pre-clinical data showed that G-CSF
could mobilize hematopoietic cells in large numbers from the
marrow into the circulation with increased progenitor cells of all
lineages detected in the spleens of G-CSF treated mice [34]. The
following year Duhrsen et al. conﬁrmed the mobilizing activity of
G-CSF in cancer patients [35]. Subsequent clinical trials demon-
strated that adequate numbers of these cells could be collected
from cancer patients or normal donors to allow successful
autologous and allogeneic HCT respectively [36–38]. The use of
G-CSF mobilization had the advantage of increasing the number of
hematopoietic cells collected, with consequent reductions in the
time taken post-transplant to restore neutrophil and platelet
numbers to clinically safe levels, and improvements in transplant
safety [39]. In addition, despite common side effects of G-CSF such
as bone pain, experience in randomized clinical trials was that
normal donors preferred donation of hematopoietic cells collected
from blood, rather than from pelvic marrow [40]. These clinical
trials have led to the widespread use of G-CSF-mobilized
hematopoietic cells collected by leucapheresis in the majority of
autologous and allogeneic transplants.
3.2. Mechanism of mobilization
The biology underlying the process of HSC mobilization has
been extensively studied but our understanding of the process is
still incomplete. Perhaps surprisingly G-CSF does not mobilize HSC
and progenitors by a direct inﬂuence on these cells. This was
demonstrated using mice that were chimeric for expression of the
G-CSFR on hematopoietic cells. In these animals hematopoietic
progenitors lacking the G-CSFR were mobilized with equivalent
efﬁciency as those expressing the receptor [41]. However, mice
where all hematopoietic cells lack the G-CSFR completely fail to
mobilize. Together this suggests that while the response of
hematopoietic cells to G-CSF is essential for HSC mobilization,
the effect is indirect and a speciﬁc response of individual HSC to G-
CSF not required.
3.2.1. Breaking the bond
The notion that HSC reside in a niche within the bone marrow
that regulates their growth, survival and differentiation has been
long held [42]. For mobilization to occur the bond between the HSC
and the niche needs to be broken. A number of retentive factors
have been identiﬁed over the last two decades with the more
prominent being the very late antigen (VLA)-4/VCAM1 adhesive
interaction and the CXCL12/CXCR4 chemo-attractive interaction.There is considerable evidence that these interactions are
disrupted during G-CSF-induced HSC mobilization [43,44] and
that their isolated blockade is sufﬁcient for mobilization [45,46].
However whether the disruption of these pathways is a necessity
in all settings remains less certain.
3.2.2. Proteases in mobilization
Initially it was demonstrated, using antibody depletion, that
neutrophils were required for HSC mobilization [47]. This led to the
hypothesis that neutrophil proteolytic enzymes were required to
cleave key microenvironmental retention factors, most notably
CXCL12 [44] and VCAM1 [43]. These molecules are cleaved in a
manner consistent with the activity of neutrophil proteases
following G-CSF administration and inhibition of these enzymes
can reduce the extent of mobilization [47]. However, attempts to
demonstrate a role for these enzymes using genetically modiﬁed
animals have been unsuccessful, with mice lacking individual or
combinations of these enzymes demonstrating normal HSC
mobilization [48]. Cleavage of VCAM1 did not occur in the protease
deﬁcient mice, suggesting that cleavage of VCAM1 is not essential for
HSC mobilization following G-CSF administration. In contrast,
functional CXCL12 and CXCR4 were both decreased in these mice
[48]. The only protease that has a demonstrated role in HSC
mobilization using genetic models is the amino-dipeptidase, CD26,
the deletion of which attenuates but does not completely block
mobilization of hematopoietic progenitors [49]. CXCL12 [50], but
not CXCR4, is a target of CD26, but CD26 also cleaves a large numbers
of other cytokines and chemokines including G-CSF [50,51].
Precisely which CD26 targets are important for G-CSF induced
HSC mobilization is not clear. Intriguingly, the lack of CXCL12
cleavage in CD26/ mice treated with G-CSF has not been
demonstrated. It would be interesting to know whether CD26 is
responsible for CXCL12 cleavage in response to G-CSF in vivo.
3.2.3. The role of lipids
Much is known about the factors that retain HSC in the niche
but little attention has been given to mechanisms that may
encourage the egress of HSC from the bone marrow. It can be
argued that such mechanisms may not exist and that cells leave the
bone marrow in a purely stochastic manner following loss of
retentive forces. However, recent evidence suggests the bioactive
lipid sphingosine 1-phosphate (S1P) may act as an egress factor
[52–54]. S1P is a chemo-attractant for hematopoietic cells,
including HSC, an activity that is mediated by a series of G-
protein coupled receptors S1P1–S1P5, with S1P1 being the principal
receptor on HSC [55]. S1P is present at high concentrations in
plasma and low concentrations in tissues, including the bone
marrow, providing an appropriately directed gradient [56].
Although red blood cells and platelets remain potential sources
of plasma S1P, recent studies have demonstrated that non-
hematopoietic cells, predominantly endothelial cells, are respon-
sible for the bulk of circulating S1P [57–59]. S1P, and its receptor
S1P1, have been repeatedly implicated in HSC mobilization by
CXCR4 antagonists, with gene deletion or pharmacological
suppression of S1P1 and genetic or pharmacological attenuation
of the S1P gradient reducing HSC mobilization [52,53]. The role of
S1P1 in G-CSF mediated mobilization is less clear with a minority of
studies showing a signiﬁcant effect [53] while most failed to detect
any interaction [52,60]. Clariﬁcation of the contribution of S1P1 in
G-CSF mediated HSC mobilization awaits further studies.
A transient increase in S1P plasma concentrations observed in
mice has been thought to be involved in HSC mobilization
following G-CSF administration. This has been explained by
increased release of S1P from red cells due to activation of the
complement cascade and the membrane attack complex and
increased S1P production by sphingosine kinase 1, combined with
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However elevated plasma S1P has not been detected in
humans mobilized with AMD3100 or G-CSF [52]. The evidence
that increased plasma S1P concentrations are required for HSC
bone marrow egress requires veriﬁcation and it appears that
baseline S1P plasma concentrations may be sufﬁcient for HSC
mobilization.
3.2.4. Microenvironmental disruption
G-CSF has profound effects on the bone marrow including the
obvious and readily explained increase in myeloid cell numbers,
but also some less easily explained cell losses, particularly cells of
mesenchymal origin. Particularly well studied are the effects on
the bone endosteal surface speciﬁcally the loss of osteoblasts [61],
and an increase in osteoclast activity [62]. Acute deletion of
osteoblasts, using an elegant double transgenic model permitting
the speciﬁc deletion of these cells by diphtheria toxin, resulted in
HSC mobilization without G-CSF. This demonstrates that osteo-
blasts are required for the optimal retention of HSC and their loss is
sufﬁcient for HSC mobilization [63]. Bone turnover has been
associated with G-CSF-induced mobilization in a number of
models, including reduced mobilization when osteoclasts are
inhibited by calcitonin or maturation blocked by gene deletion of
PTPRE (protein tyrosine phosphatase, receptor type, E) or CD45.
Osteoclasts could provide enzymes to degrade microenvironmen-
tal components in a similar manner to neutrophil enzymes [62,64].
However osteoclasts are not essential for G-CSF-induced HSC
mobilization [65] and some reports suggest that the timing of
increased osteoclast numbers is not consistent with peak
mobilization times [66,67]. More recently loss of other cells
including osteomacs, specialized macrophages that blanket
osteoblasts [66], and osteocytes, located within the bone [68]
has been reported during G-CSF mediated mobilization. In contrast
the more vascular associated CXCL12-abundant reticular (CAR)
cells and nestin-positive mesenchymal stem cells (N+MSC) appear
to be unchanged in numbers.
3.2.5. The role of phagocytes
More recently phagocytic cells have been implicated in the
process of mobilization, with restoration of G-CSF receptor
expression on CD68+ monocytes in otherwise G-CSF receptor null
mice being sufﬁcient for HSC mobilization by G-CSF [69]. The
neutropenic nature of these mice also suggests that neutrophils are
not essential for HSC mobilization, although it does not eliminate
their involvement in the process in normal animals. G-CSF-induced
mobilization in this model was associated with the loss of
monocytes from the bone marrow and suppression of osteoblasts.
A similar loss of macrophages speciﬁcally associated with
osteoblasts in the bone marrow, termed osteomacs [66], was also
reported following G-CSF administration. Furthermore, depletion
of osteomacs [66] or CD169+ macrophages [70] is sufﬁcient to
mobilize HSC. While there are clear parallels relating to the
involvement of the monocyte/macrophage lineage in G-CSF
induced HSC mobilization different underlying mechanisms have
been proposed to explain these effects. Osteomacs have been
proposed to act by providing protection and support for
osteoblasts [66], which once lost leads to the typical suppression
of osteoblast numbers and function associated with G-CSF-induced
HSC mobilization. In contrast, the CD169+ macrophages were
shown to promote CXCL12 production by N+MSC but not
osteoblasts in vitro [70], with loss of macrophages in vivo reducing
CXCL12 gene expression by N+MSC. Whether CD169+macrophages
are lost following G-CSF administration has not been addressed at
this stage. Overall these studies suggest that monocyte derived
macrophages play a signiﬁcant role in G-CSF induced HSC
mobilization, apparently resulting from a G-CSF induced loss ofthese cells, their supportive function for cells of mesenchymal
origin and ultimately CXCL12 production. The details regarding
precisely which macrophages are key and the identiﬁcation of
mesenchymal cells inﬂuences awaits further conﬁrmation by
others.
3.2.6. The role of the nervous system
G-CSF-induced mobilization is severely inhibited in mice where
the sympathetic nervous system is disrupted by genetic or
pharmacological means [71], implicating an active role for the
nervous system in G-CSF-mediated HSC mobilization. Both b2 and
b3-adrenergic receptors appear to co-operate in this process [72].
G-CSF does not seem to affect the release of norepinephrine from
sympathetic neurons but reduces the subsequent uptake, thereby
increasing the strength/duration of signals from the sympathetic
nervous system [73]. Neurotransmitters could have a direct effect
on HSC as human CD34+ cells express b2-adrenergic and dopamine
receptors, the stimulation of which enhances responses to the
chemokine CXCL12 [74]. Furthermore, G-CSF increased the
expression of b2-adrenergic and dopamine receptors on these
cells. However, the in vitro studies found the response of HSC to
catecholamines to be modest compared to the potent in vivo effects
observed, suggesting that the effects of the sympathetic nervous
system on the bone marrow microenvironment may be more
important.
Many of the G-CSF-induced microenvironmental changes
appear to be mediated by the sympathetic nervous system
including reductions in osteoblasts and osteocytes [68,71]. The
responses of osteoblasts to sympathetic signals are dependent on
expression of the vitamin D receptor, which is increased by
stimulation through the b2-adreneric receptor [75]. One of the
more surprising ﬁndings of these recent papers is that despite the
failure to mobilize HSC, CXCL12 expression is still drastically and
promptly reduced in the bone marrow in response to G-CSF when
osteocytes, the sympathetic nervous system or vitamin D receptor
are disrupted [68,71,75]. This ﬁnding appears to conﬂict with the
now long held and well supported concept that CXCL12 is critical
for the retention of HSC in the bone marrow and prevention of
CXCL12 binding its receptor CXCR4 is pivotal to HSC mobilization
[44,76]. Each of these three models result in some disruption of the
endosteal niche, so it has been suggested that alternate retention
factors may compensate for the altered niche in these mice
reducing the importance of the CXCL12/CXCR4 axis [68]. However,
in each of these models HSC mobilization by the CXCR4 antagonist
AMD3100 was unaffected demonstrating that disruption of
CXCR4/CXCL12 alone is still able to mobilize HSC and conﬁrming
the importance of CXCL12 in HSC retention and its role in
mobilization. Another possibility is that despite the overall
decrease in CXCL12 concentrations in the extracellular ﬂuid of
the bone marrow of these gene-modiﬁed mice when G-CSF is
administered, CXCL12 concentrations may not be adequately
reduced within the HSC niche itself. At least in the osteocyte model,
CXCL12 protein expression was found to be high in the bone matrix
and was not decreased following osteocyte ablation.
Evidence for the involvement of the sympathetic nervous
system in G-CSF-induced HSC mobilization in humans is limited.
A recent study linked low circulating CD34+ cells with increased
markers for diabetic neuropathy [77] and although mobilization
was not measured in this study, diabetic patients have been
shown to mobilize poorly [78]. However, a retrospective
examination of allogeneic donors undergoing HSC mobilization
failed to reveal better CD34+ cell mobilization in patients who
were coincidentally taking b-blockers for other reasons but
numbers of patients were small and a larger controlled
prospective study would be needed to clarify the importance
of this axis in human HSC mobilization [79].
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Overall at a cellular level it appears that G-CSF triggers a
number of potentially parallel events including expansion of
neutrophils and their precursors, stimulation of CD169+ bone
marrow macrophages, the peripheral sympathetic nervous,
osteocytes and osteomacs (Fig. 1). The latter three either directly
or indirectly suppress osteoblasts and the production of bone
marrow supportive factors, notably CXCL12. The stimulation of
CD169+ macrophages, potentially via the sympathetic nervous
system, suppresses CXCL12 production by N+MSC. The granulocyte
expansion provides a proteolytic environment that can degrade
retentive factors. Together this results in alteration to the HSC
niche making it less attractive for HSC, permitting their egress intoFig. 1. The upper panel shows resting bone marrow and the lower panel G-CSF treated m
catecholamines. Under resting conditions HSC are held within the bone marrow by adhe
expansion of neutrophils and their precursors, creating a proteolytic environment leading
also stimulates the peripheral sympathetic nervous system, increasing catecholamine con
production by Nestin+ MSC via effects on CD169+ bone marrow macrophages. Osteomacs
by these cells. CXCL12 production by CAR cells is also decreased. Together this results in a
microenvironment. Osteoclast numbers expand, increasing bone turn over. In the abse
gradient facilitating the movement of HSC from the niche into the peripheral circulatiothe peripheral circulation potentially under the inﬂuence of a S1P
gradient.
3.3. Inadequate stem cell mobilization
3.3.1. Normal donors
Despite the great success of G-CSF as a mobilizing agent a
number of concerns remain. Although the majority of healthy
allogeneic donors mobilize adequately, insufﬁcient cells are
recovered from a small proportion, particularly when there is a
major weight discrepancy between donor and recipient. A few
features such as the female donor sex and G-CSF dose scheduling,
and in some studies basal platelet count, have been associated witharrow. The yellow shading indicates CXCL12, the red shading S1P and the red stars
sive interactions and the chemo-attraction provided by CXCL12. G-CSF triggers the
 to the degradation of adhesive interactions, chemokines and their receptors. G-CSF
centrations, which in turn suppresses osteocytes and osteoblasts as well as CXCL12
 are also suppressed facilitating the reduction in osteoblasts and CXCL12 production
 dramatic decrease in the concentrations of this chemokine within the bone marrow
nce of CXCL12 and adhesive interactions, HSC are now able to respond to the S1P
n.
L.J. Bendall, K.F. Bradstock / Cytokine & Growth Factor Reviews 25 (2014) 355–367360lower HSC yields. However, the predominant reason for the
variation between donors appears to be linked to the genetics of
the donor as the same donor mobilized on separate occasions
results in a very similar HSC recovery. The CXCL12–30A allele has
been associated with better mobilization in most [80–83],
although not all studies [84]. The CC genotype of the CD44
polymorphism rs13347 has been associated with better CD34+ cell
yields in two studies, one in healthy and one in autologous donors,
although the binning of the heterozygotes differed between the
studies [83,85]. These same studies had conﬂicting outcomes
regarding polymorphisms in VCAM1 (rs1041163), CXCR4
(rs2680880), and the G-CSF receptor (rs3917924) with only the
study by Martin-Antonio and colleagues ﬁnding negative associa-
tions with the CC and AA genotypes of VCAM1 and CXCR4
respectively, and total CD34+ yield and the CC and TT genotypes of
VCAM1 and the G-CSF receptor respectively and CD34+ cells/ml in
the blood prior to collection. Overall it appears that the extent of
mobilization is moderated by genetic polymorphisms in the
molecules involved in migration and homing of HSC.
3.3.2. Following chemotherapy
In autologous donors mobilization failure is more common and
is strongly correlated with prior exposure to myelotoxic agents
with DNA damaging agents such as melphalan and ﬂudarabine and
the thalidomide derivative lenalidomide [86–88]. This is thought
to be partly due to stem cell depletion by chemotherapy exposure,
but also partly due to damage to the niche, with a number of
reports describing long-term stromal damage resulting from high
dose chemotherapy in animals models and patients [89–92]. A
recent paper demonstrated in mice that impaired bone marrow
function following vincristine and cisplatin exposure resulted from
damage to sympathetic neurons. Protection of neurons in this
model using 4-methylcatechol, reduced the loss of bone marrow
niche cells including N+MSC and endothelial cells following
exposure to neurotoxic chemotherapy, although osteoblasts and
macrophages were not affected. Animals with chemotherapy
induced sympathetic nervous system damage mobilized poorly
with G-CSF and protection of the sympathetic nervous system
during chemotherapy could prevent this impaired mobilization
[93]. This study suggests that the use of drugs to prevent or
minimize nerve damage during induction chemotherapy could
minimize mobilization failure during subsequent stem cell
transplantation procedures.
3.3.3. Diabetic donors
A retrospective analysis revealed an association between
elevated blood sugar and a failure to adequately mobilize HSC
in response to G-CSF [63]. This ﬁnding was recently conﬁrmed in a
prospective clinical trial [78]. The association between diabetes
and mobilization failure was replicated using two separate mouse
models of diabetes and was shown using transplantation experi-
ments to result from altered microenvironmental conditions.
Consistent with this, diabetic mice had reduced osteoblast
numbers and although normal in number the N+MSC expressed
less CXCL12 and importantly failed to down-regulate CXCL12
following G-CSF treatment. The failure to down-regulate CXCL12
was due to dysfunction of the sympathetic nervous system in
diabetic mice. This is consistent with previous reports of bone
marrow neuropathy in diabetic rats [94] and neuropathies in
human diabetic patients [95].
3.4. Side-effects
Another issue relating to the use of G-CSF for HSC mobilization,
particularly in normal donors, is its side effects. G-CSF can induce a
considerable number of short-term side effects, the majority ofwhich are not serious, although undoubtedly uncomfortable, such
as malaise, nausea, night sweats, with the most commonly
reported being bone pain [96–99]. However a small number of
serious events have been reported, with splenic rupture being the
most prominent, but interstitial pneumonitis, pulmonary inﬁl-
trates, lung ﬁbrosis and respiratory distress syndrome have also
been described [100,101]. Improved mobilization strategies are
desirable to minimize the risk, particularly to healthy donors, of
these adverse events.
3.5. Improving mobilization strategies
The need to improve mobilization protocols, particularly in
autologous settings with heavily pretreated patients, is essential to
achieve better transplantation outcomes. A number of agents, most
commonly cytokines including GM-CSF, FLT3L, IL8 and SCF, have
long been known to induce HSC mobilization alone or in
combination with G-CSF [102–105] but have not entered routine
clinical use for a variety of reasons and these will not be discussed
here. Here we will focus on agents or strategies with the potential
for clinical application in the future.
3.5.1. CXCR4 antagonists
A simple but logistically challenging possibility is to make
optimal use of the natural circadian rhythm by harvesting donors
during the evening [106], taking advantage of normal modulations
in CXCL12 and CXCR4 expression in the bone marrow and on HSC
respectively. In the last decade pharmacological manipulation of
this axis has become available. The leading CXCR4 antagonist
AMD3100 was ﬁrst approved by the Food and Drug Administration
in the USA in 2008 for use in combination with G-CSF to mobilize
HSC for autologous transplantation in patients with non-Hodgkin
lymphoma and multiple myeloma, and is now commonly used
world-wide in this setting. Pre-clinical studies in mice also suggest
that CXCR4 antagonists such as AMD3100 may be useful in
overcoming the reduced mobilization seen in diabetic patients
[63]. Unlike G-CSF, where the mechanism of mobilization is
complex, CXCR4 antagonists mobilize HSC by blocking the
retentive activity of CXCL12. As a result they have a rapid effect,
with a peak mobilization at about one hour in mice and nine hours
in humans [46,107]. Although inhibition of the CXCL12/CXCR4 axis
is considered key to G-CSF-mediated HSC mobilization, CXCR4
antagonists are relatively modest mobilizers when used in
isolation but display considerable synergy when combined with
G-CSF [107]. This suggests that suppression of CXCL12 in the bone
marrow is less than complete following G-CSF treatment, leaving
room for further inhibition by a CXCR4 antagonist. However there
is an alternative explanation. Peripheral blood HSC numbers are
signiﬁcantly increased by prior splenectomy when mobilizing with
G-CSF [108] but this is not observed when AMD3100 is the
mobilizing agent [109]. CXCL12 is not only present in the bone
marrow but is expressed in many other tissues such as the spleen,
lungs and liver [110,111] and so has the potential to retain, at least
transiently, circulating HSC in these tissues. Massberg and co-
workers elegantly demonstrated the trafﬁcking of HSC through
peripheral tissues under basal conditions, although this appears to
occur at a low rate [60]. A systemically administered CXCR4
antagonist would be expected not only to mobilize HSC from the
bone marrow but also from peripheral tissues, and prevent
transient retention in these sites. It is therefore possible that the
reduced loss of HSC to peripheral tissues, particularly the spleen, in
the presence of CXCR4 antagonists contributes to the increased
circulating HSC numbers when CXCR4 antagonists are combined
with G-CSF.
Although AMD3100 is currently the only approved CXCR4
antagonist in clinical use, a large number of compounds have been
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in Debnath et al.) [112]. Only agents with potential for clinical
translation for HSC mobilization will be discussed here (Table 1).
POL6326 and TG-0054 are the most advanced and currently in
clinical trial for HSC mobilization, and both have undisclosed
structures. POL6326 is currently in a safety study in normal
volunteers (NCT01841476) and a Phase I/II clinical trial for the
mobilization of sibling donors (NCT01413568). Results in normal
volunteers showed it was well tolerated and effectively mobilized
CD34+ cells [113]. Preliminary results from a Phase II study forTable 1
Potential mobilizing agents.
Agent Mechanism Structure 
AMD3100 CXCR4 antagonist 
POL6326 CXCR4 antagonist Not available 
TG-0054 CXCR4 antagonist Not available 
KRP203 CXCR4 antagonist 
Me6TREN Unknown 
BIO5192 VLA-4 antagonist 
MRS2690 P2RY14 agonist 
GSK2018682 S1P1 agonist 
ACT-128800 S1P1 agonist patients with multiple myeloma undergoing autologous HSC
transplantation (NCT01105403) demonstrated adequate mobili-
zation of CD34+ cells in 66% of patients with all of these achieving
engraftments. A small number of malignant cells were detected in
the POL6326 mobilized product in 3 of 5 patients tested but this
was not considered to be greater than expected using G-CSF and
chemotherapy [114]. POL6326 has not been tested in combination
with G-CSF. The requirement for intravenous administration
represents a minor disadvantage to this agent particularly for
normal volunteers.Developmental stage
Approved for use in combination
with G-CSF for autologous
transplantation.
Phase 1 and Phase 2 clinical trials
for mobilization in healthy donors
and patients with hematological
malignancies.
Phase 1 trials in healthy donors
completed and phase 2 trials in
patients with hematological
malignancies, some ongoing.
Phase 1 trial in patients with
hematological malignancies.
Preclinical testing in mice.
Preclinical testing in mice
Preclinical testing in mice.
Phase 1 trials in healthy
volunteers completed.
Phase 1 trials in healthy
volunteers and Phase 2
studies for autoimmune
disease.
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similar to AMD3100 but achieved a peak HSC mobilization closer
to that obtained with G-CSF [115]. TG-0054 has completed safety
studies in normal volunteers and patients with multiple
myeloma, non-Hodgkin lymphoma and Hodgkin disease, where
it was well tolerated and induced the mobilization of CD34+ cells,
peaking between 4 and 6 h with acceptable CD34+ cell counts of
greater than 20/ml in healthy volunteers [116]. TG-0054 is
currently being evaluated in a Phase II trial for autologous
transplantation as a single agent and in combination with G-CSF
(NCT01458288). A preliminary report showed that 7 of 12
patients with advanced hematological malignancies were
adequately mobilized with TG-0054 alone and the remaining 5
patients with a combination of G-CSF and TG-0054. All patient
successfully engrafted with the mobilized products [117]. Both
POL6326 and TG-0054 have the potential to be used as single
agents and therefore could replace G-CSF for HSC mobilization in
some settings in the future. In addition to these compounds a
new inhibitor ALT-1188 was described at the 2013 American
Society for Hematology (ASH) meeting demonstrating superior
mobilization in mice than AMD3100 [118]. It is a small molecule
inhibitor with an azacarbazole backbone linked via a short chain
alkyldiamine to a tetrahydroquinoline eliminating the metal-
chelating properties of AMD3100, potentially reducing toxicity.
The application of this compound in humans remains to be
determined.
3.5.2. VLA-4 inhibitors
VLA-4 binding to VCAM1 and to a lesser extent ﬁbronectin and
osteopontin provides a major adhesive interaction for HSC within
the bone marrow microenvironment, the disruption of which leads
to HSC mobilization [109,119]. As with CXCL12/CXCR4 interac-
tions, G-CSF treatment disrupts VLA-4/VCAM1-mediated bone
marrow retention [43], and inhibition of VLA-4/VCAM1 binding
enhances the efﬁcacy of G-CSF [119]. A small molecule inhibitor of
VLA-4 binding, BIO5192, has been developed and as anticipated,
increases the degree of mobilization induced by G-CSF in mice
[109]. Whether this or a next generation VLA-4 antagonist will ﬁnd
a place in clinical mobilization strategies remains to be deter-
mined.
3.5.3. UDP-glucose
Recently the nucleotide sugar UDP-glucose was shown
to mobilize HSC in mice. In contrast to most mobilizing
agents described to date, UDP-glucose preferentially mobilized
the most primitive cells and did not result in a general
leukocytosis [120]. The mobilized stem cells were
more quiescent than those mobilized by G-CSF and demonstrat-
ed greater long-term repopulating activity with a distinct
skewing toward the lymphoid lineages. The effect was indepen-
dent of the G-CSF receptor but dependent on the generation
of reactive oxygen species and apparently through the induction
of RANK ligand and osteoclast activity. While UDP-glucose
synergized with G-CSF the mechanism of action appeared to
differ from when it was use in isolation, perhaps questioning
whether the proposed mechanism is correct. The receptor
for UDP-glucose is thought to be P2RY14 [121], although this is
a subject of debate [122,123] and hence was not directly
examined. The authors proposed that the small molecule agonist
of P2RY14, MRS 2690, could be a useful agent, however
safety data for this compound are not yet available. In
mice the administration of UDP-glucose did not induce any
measurable toxicities. The very primitive nature of the HSC
mobilized resulted in delayed engraftment, suggesting that it
may not be useful as a single agent but better combined with G-
CSF.3.5.4. Agonists of S1P1
Amplifying the S1P gradient between the blood and bone
marrow provides a potential mechanism to increase HSC
trafﬁcking into the peripheral blood. While the S1P receptor
agonist SEW2871 had no signiﬁcant effect on circulating HPC
numbers when used alone or in combination with G-CSF in mice,
it signiﬁcantly enhanced mobilization induced by AMD3100 in
both good and poor mobilizers and the combination of AMD3100
and G-CSF in good mobilizers only [52]. This suggests that S1P1
agonists may be used in combination with CXCR4 antagonists,
eliminating the need for G-CSF in some settings. A potential
advantage of the use of S1P1 agonists is that the increased
mobilization was not associated with increased total peripheral
white blood counts. Considering that agonists of S1P1 that induce
receptor internalization result in the retention of lymphoid cells
in secondary lymphoid tissues such as spleen and lymph nodes, it
is likely that these agents will change the immune make up of the
harvested graft, with a likely skewing away from naive to
memory T cells. This has the potential to reduce graft versus host
disease.
There are an increasing number of S1P receptor agonists at
various stages of development, with those that have entered
clinical trial being examined for the known immunosuppressive
activity of these agents in conditions such as multiple sclerosis
(GSK2018682, ACT-128800 and FTY720) psoriasis (ACT-128800),
sub-acute cutaneous lupus erythematosus and ulcerative colitis
(KRP203), Rett’s syndrome and asthma (FTY720) and the
prevention of graft vs host disease (KRP203). Indeed FTY720
is currently approved for the treatment of multiple sclerosis. All
of these agents mediate their effects by inducing internalization
and loss of function of S1P receptors. Only SEW2871 is known to
activate S1P1 without inducing internalization, a feature
desirable for use as a mobilizing agent [124]. However,
SEW2871 has not been tested in humans and due in part to
its poor solubility is unlikely to be useful clinically. Perhaps the
biggest problem facing the development of S1P1 agonists in HSC
mobilization are the cardiac effects of S1P1 agonists with these
agents producing pronounced transient bradycardia [125].
Considering acute high doses will be needed for mobilization
strategies the development of an ideal agent represents a
signiﬁcant challenge.
3.5.5. Me6TREN
Me6TREN is a novel small molecule identiﬁed from a
chemical screen that induces the mobilization of HSC as a
single agent and enhances HSC mobilization when combined
with G-CSF or AMD3100 [126]. The mechanism of action of
Me6TREN involves the induction of MMP9 expression via
phosphoinositide-3 kinase and p38 mitogen-activated protein
kinase pathway signaling. Although Me6TREN inhibits CXCL12
induced chemotaxis direct evidence of receptor binding is
lacking. The agent demonstrated safety and efﬁcacy in mice but
remains to be tested in humans.
4. Mobilization of malignant cells
The bone marrow microenvironment provides a supportive
environment not only for normal hematopoietic stem and
progenitor cells but also malignant hematopoietic cells includ-
ing leukemias [127–129]. This environment also provides
protection from chemotherapeutic agents [130,131], potentially
facilitating the survival of small numbers of residual cells
that can ultimately lead to disease relapse. This has led to
the concept that disruption of leukemic cell interactions with
the bone marrow microenvironment could be used to therapeu-
tic advantage. In AML the stimulatory effects of G-CSF on
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cycle dependent chemotherapeutic agents in vitro [132], could
theoretically augment any effects of G-CSF on stromal mediated
support deprivation through disruption of the bone marrow
niche (Fig. 2). Disappointingly, several randomized clinical trials
incorporating G-CSF with induction chemotherapy for AML
failed to show a signiﬁcant beneﬁt in leukemia-free survival
[133–136], although two studies have shown improvements in
subpopulations of patients [137], most recently in patients
receiving dose escalation of cytarabine [138]. However agents
such as inhibitors of CXCR4 or VLA4, that mobilize AML cells
from the bone marrow without having direct proliferative
effects have demonstrated beneﬁt in pre-clinical settings
[131,139]. Clinical data have suggested that mobilization of
AML blasts can be achieved safely in patients [140] but the
beneﬁt, if any, waits the outcome of current clinical trials.
Results in chronic myeloid leukemia have been less promising
with conﬂicting data from two studies using CXCR4 antagonists
with one reporting increased CNS involvement following
treatment with Plerixafor [141,142].
In contrast, B cell malignancies only rarely express the G-CSF
receptor [143] and so are unable to respond directly to
this cytokine. Preclinical studies targeting CXCR4 and VLA-4
have produced promising results in in vivo models of acuteFig. 2. The upper panel shows the response of the bone marrow chemotherapy, with pr
resulting in disease relapse. In the lower panel G-CSF reduces the niche and induces 
hematopoietic cells (purple) can then expand once chemotherapy is completed.lymphoblastic leukemia (ALL) suggesting that microenviron-
mental disruption may be of therapeutic beneﬁt [144,145]. While
G-CSF has been given to many patients with lymphoid
malignancies to facilitate chemotherapy delivery and support
hematopoietic stem cell transplantation, it has not been
administered prior to chemotherapy with the intention of
disrupting the microenvironment for the purpose of enhancing
chemo-sensitivity. A clinical trial (NCT01331590) examining the
potential of priming the bone marrow with G-CSF is currently
being conducted with preliminary data presented at the ASH
meeting in 2013 [146]. Although the baseline bone marrow
microenvironment was highly disrupted in relapsed and
refractory ALL patients, CXCL12, although not IL-7 or osteocalcin
mRNA was reduced in the majority of patients after 4 days of G-
CSF. While there was no measurable effect on ALL blast
proliferation, apoptosis was increased in response to G-CSF
priming in the 3 patients tested. A pre-clinical study of human
ALL in NOD/SCID gamma/c/ mice presented at the previous
meeting suggested that this strategy may not be beneﬁcial for all
patients, with 2 of 6 xenografts tested demonstrating increased
tumor burden following 10 days of G-CSF compared to control
treated animals bearing the same xenograft [147]. Whether G-
CSF priming will lead to measurable increases in chemo-
sensitivity awaits the outcome of clinical trials.oliferating AML cells (red) dying while quiescent AML cells (maroon) are resistant
proliferation in quiescent AML cells facilitating killing by chemotherapy. Normal
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Today G-CSF is an established therapeutic agent routinely
used for the management of neutropenia, reducing morbidity,
particularly in cancer patients undergoing chemotherapy. G-CSF
has also been fundamental to the transition from bone marrow
to peripheral blood as the source of hematopoietic stem cells for
transplantation, increasing the safety, efﬁciency and broadening
the applicability of the procedure. While the use of G-CSF in
stem cell mobilization is well established, there is scope for
improvement of this procedure and new agents are emerging,
hopeful of bridging the shortcomings and possibly, at least in
some settings, replacing G-CSF. Looking to the future, elucida-
tion of the mechanisms of action of G-CSF as a stem cell
mobilization agent have delineated a number of potential
pathways whereby disruption of the bone marrow stem cell
niche may be exploited to enhance the efﬁcacy of current
treatment protocols for the leukemias. While G-CSF is clearly a
well established therapeutic, its use continues to evolve,
becoming more sophisticated as its application expands into
new areas.
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